Yixuan Zhang

Yixuan Zhang

Auto-generated profile, based on publicly available information

Yixuan Zhang

Department of Gastroenterology Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu Province 210008 P. R. China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Advanced Science
Verified
Journal Article
Open access
YZYin Zhang
Yin Zhang
RYRanran Yu
Ranran Yu
CZCheng Zhao
Cheng Zhao
JLJiawei Liang
Jiawei Liang
YZYixuan Zhang
Yixuan Zhang
YLYing Lv
Ying Lv
BRD4 is a member of the BET protein family involved in chromatin remodeling and transcriptional regulation. Several BET inhibitors (BETi) have entered clinical trials, demonstrating potential in inducing cancer cell apoptosis and tumor regression. However, resistance to BETi is common in solid tumors. In pancreatic cancer, it is found that cancer‐associated fibroblasts (CAFs) in the tumor microenvironment reduce the BET inhibitor JQ1 sensitivity by inducing BRD4 expression. Moreover, CAFs play a crucial role in the formation of a dense stromal barrier. Therefore, targeting CAFs in the tumor microenvironment of pancreatic cancer not only enhances cancer cells sensitivity to JQ1 but also increases drug perfusion and improves oxygen supply, thus reducing glycolysis and limiting energy supply. To address this challenge, a homologous targeting mechanism utilizing activated fibroblast membrane‐coated liposomes is proposed for specific drug precise target to CAFs‐rich pancreatic cancer. Additionally, TAT peptides enable liposomes penetration, delivering PFD for targeted anti‐fibrotic therapy, reducing extracellular matrix generation and glycolysis, and enhancing JQ1 delivery and sensitivity. In conclusion, the findings indicate the tremendous potential of this CAFs‐targeting liposomal delivery system in pancreatic cancer.

12 May 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
YZYixuan Zhang
Yixuan Zhang
JWJianzhuang Wu
Jianzhuang Wu
YFYao Fu
Yao Fu
RYRanran Yu
Ranran Yu
HSHaochen Su
Haochen Su
SZShu Zhang
Shu Zhang